Jan 20, 2025 · Verzenio is available as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Verzenio storage. Store Verzenio at room temperature between 68°F to 77°F (20°C to 25°C). Keep out of the reach of children. Who makes Verzenio? Verzenio is manufactured by Eli Lilly and Company (commonly known as Lilly), headquartered in Indianapolis, Indiana.

May 23, 2024 · Verzenio is a brand (trade) name for abemaciclib which may be used to treat certain types of breast cancer. Verzenio (abemaciclib) works by inhibiting two particular enzymes, called CDK4 and CDK6. CDK stands for cyclin-dependent kinase, and it is an enzyme that is important for cell division.

Mar 20, 2023 · Verzenio plus endocrine therapy (ET) decreases the risk of breast cancer recurrence by 35% compared to ET alone. 4-year data from the monarchE trial showed 85.5% of patients remained recurrence-free after 4 years compared to 78.6% of those assigned ET alone (an absolute difference of 6.9%).

Nov 25, 2024 · VERZENIO ® is a kinase inhibitor indicated: . in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.

Aug 24, 2023 · Some dosage forms listed on this page may not apply specifically to the brand name Verzenio. Applies to abemaciclib: oral tablet. Serious side effects of Verzenio. Along with its needed effects, abemaciclib (the active ingredient contained in Verzenio) may cause some unwanted effects. Although not all of these side effects may occur, if they do ...

Jan 20, 2025 · Verzenio is considered a targeted treatment, rather than being a chemo drug, but it may be used to treat certain types of breast cancer. Verzenio belongs to the class of medicines known as CDK 4/6 inhibitors which help to reduce the growth and spread of …

Dec 11, 2024 · Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is currently authorized for use in more than 90 counties around the world.

Nov 6, 2024 · Verzenio in early breast cancer The monarchE study looked at 2,003 eligible women and men with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. Patients were randomized to receive two years of Verzenio 150 mg twice daily plus physician's choice of hormone therapy, or hormone therapy alone.

Nov 13, 2024 · Table 2: VERZENIO Dose Modification and Management — Hematologic Toxicities a Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events. a If blood cell growth factors are required, suspend VERZENIO dose for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to ≤Grade 2.

Jan 20, 2025 · Patients taking Verzenio are more likely to live for longer without their breast cancer getting worse according to a recent retrospective trial. Severe diarhhea is more likely in those taking Verzenio compared with Ibrance. Verzenio is taken twice daily, every day. Ibrance is taken every day for 21 days followed by a 7-day break.